American Society of Hirudotherapy

Face autotransplantation after an accident

Case report published in J Craniofac Surg (2022)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportClinical LiteratureKim KS et al. · The Journal of craniofacial surgery, 2022

Abstract

Microsurgical replantation is considered the best method to treat avulsion or amputation injuries of unique head parts, including the scalp, eyelid, nose, ear, lip, and tongue. However, there is currently no report on microsurgical replantation of substi-tutable facial tissues in the literature. This report presents a patient with avulsed facial composite tissue composed of the skin and subcutaneous layers treated by microsurgical replantation. The present case shows that microsurgical replantation of small facial composite tissues is feasible. The authors suggest that the indication spectrum for microsurgical replantation should be expanded beyond current clinical practice.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAccidentsAmputation, TraumaticFacial TransplantationHumansMaleMicrosurgeryMiddle AgedScalpTransplantation, AutologousTreatment Outcome

Summary

A case report describes microsurgical replantation of avulsed facial composite tissue composed of skin and subcutaneous layers in a patient, demonstrating this approach is feasible; no prior report existed on replanting such substitutable facial tissues, and the authors suggest expanding replantation indications beyond current practice.

Context

This case report presents microsurgical replantation of avulsed facial composite tissue (skin and subcutaneous layers) following trauma, demonstrating feasibility of the technique and suggesting expansion of indications for microsurgical replantation. The abstract focuses entirely on surgical replantation methodology and outcomes. There is no mention of leeches, hirudotherapy, hirudin, or any leech-derived substance. Leech therapy is sometimes employed in reconstructive surgery for venous congestion management, and this report does not document such use.

Citation

Reference (Vancouver style)

Kim KS, Oh SS, Choi JH, Hwang JH, Lee SY. Face autotransplantation after an accident. J Craniofac Surg. 2022;33(4):e346-e347. doi:10.1097/SCS.0000000000008506. PMID: 35240668

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.